These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 29216346)

  • 1. Darunavir/ritonavir monotherapy at a low dose (600/100 mg/day) in HIV-1-infected individuals with suppressed HIV viraemia.
    Seang S; Schneider L; Nguyen T; Lê MP; Soulie C; Calin R; Caby F; Valantin MA; Tubiana R; Assoumou L; Marcelin AG; Peytavin G; Katlama C
    J Antimicrob Chemother; 2018 Feb; 73(2):490-493. PubMed ID: 29216346
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Virological response and resistance profile in HIV-1-infected patients starting darunavir-containing regimens.
    Armenia D; Di Carlo D; Maffongelli G; Borghi V; Alteri C; Forbici F; Bertoli A; Gori C; Giuliani M; Nicastri E; Zaccarelli M; Pinnetti C; Cicalini S; D'Offizi G; Ceccherini-Silberstein F; Mussini C; Antinori A; Andreoni M; Perno CF; Santoro MM
    HIV Med; 2017 Jan; 18(1):21-32. PubMed ID: 27353061
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term efficacy of darunavir/ritonavir monotherapy in patients with HIV-1 viral suppression: week 96 results from the MONOI ANRS 136 study.
    Valantin MA; Lambert-Niclot S; Flandre P; Morand-Joubert L; Cabiè A; Meynard JL; Ponscarme D; Ajana F; Slama L; Curjol A; Cuzin L; Schneider L; Taburet AM; Marcelin AG; Katlama C;
    J Antimicrob Chemother; 2012 Mar; 67(3):691-5. PubMed ID: 22160145
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Switching to darunavir/ritonavir 800/100 mg once-daily containing regimen maintains virological control in fully suppressed pre-treated patients infected with HIV-1.
    Ghosn J; Slama L; Chermak A; Houssaini A; Lambert-Niclot S; Schneider L; Fourn E; Duvivier C; Simon A; Courbon E; Murphy R; Flandre P; Peytavin G; Katlama C;
    J Med Virol; 2013 Jan; 85(1):8-15. PubMed ID: 23024008
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 96-week results of a dual therapy with darunavir/ritonavir plus rilpivirine once a day
    Di Cristo V; Adorni F; Maserati R; Annovazzi Lodi M; Bruno G; Maggi P; Volpe A; Vitiello P; Abeli C; Bonora S; Ferrara M; Cossu MV; Oreni ML; Colella E; Rusconi S
    HIV Res Clin Pract; 2020 Feb; 21(1):34-43. PubMed ID: 32129161
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Week 96 efficacy and safety of darunavir/ritonavir monotherapy vs. darunavir/ritonavir with two nucleoside reverse transcriptase inhibitors in the PROTEA trial.
    Girard PM; Antinori A; Arribas JR; Ripamonti D; Bicer C; Netzle-Sveine B; Hadacek B; Moecklinghoff C
    HIV Med; 2017 Jan; 18(1):5-12. PubMed ID: 27279571
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low-dose ritonavir-boosted darunavir in virologically suppressed HIV-1-infected adults: an open-label trial (ANRS 165 Darulight).
    Molina JM; Gallien S; Chaix ML; El Abbassi EM; Madelaine I; Katlama C; Valin N; Delobel P; Desseaux K; Peytavin G; Saillard J; Raffi F; Chevret S;
    J Antimicrob Chemother; 2018 Aug; 73(8):2129-2136. PubMed ID: 29860402
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual Raltegravir-Darunavir/Ritonavir Combination in Virologically Suppressed HIV-1-Infected Patients on Antiretroviral Therapy Including a Ritonavir-Boosted Protease Inhibitor Plus Two Nucleoside/Nucleotide Reverse Transcriptase Inhibitors.
    Calza L; Danese I; Magistrelli E; Colangeli V; Manfredi R; Bon I; Re MC; Conti M; Viale P
    HIV Clin Trials; 2016 Feb; 17(1):38-47. PubMed ID: 26728706
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Resistant minority species are rarely observed in patients on darunavir/ritonavir monotherapy.
    Lambert-Niclot S; Flandre P; Valantin MA; Peytavin G; Sayon S; Morand-Joubert L; Delaugerre C; Algarte-Genin M; Katlama C; Calvez V; Marcelin AG
    J Antimicrob Chemother; 2012 Jun; 67(6):1470-4. PubMed ID: 22396434
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial.
    Molina JM; Squires K; Sax PE; Cahn P; Lombaard J; DeJesus E; Lai MT; Xu X; Rodgers A; Lupinacci L; Kumar S; Sklar P; Nguyen BY; Hanna GJ; Hwang C;
    Lancet HIV; 2018 May; 5(5):e211-e220. PubMed ID: 29592840
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Once-daily dolutegravir versus darunavir plus ritonavir for treatment-naive adults with HIV-1 infection (FLAMINGO): 96 week results from a randomised, open-label, phase 3b study.
    Molina JM; Clotet B; van Lunzen J; Lazzarin A; Cavassini M; Henry K; Kulagin V; Givens N; de Oliveira CF; Brennan C;
    Lancet HIV; 2015 Apr; 2(4):e127-36. PubMed ID: 26424673
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Significant improvement in triglyceride levels after switching from ritonavir to cobicistat in suppressed HIV-1-infected subjects with dyslipidaemia.
    Echeverría P; Bonjoch A; Puig J; Ornella A; Clotet B; Negredo E
    HIV Med; 2017 Nov; 18(10):782-786. PubMed ID: 28671337
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of darunavir/ritonavir maintenance monotherapy in patients with HIV-1 viral suppression: a randomized open-label, noninferiority trial, MONOI-ANRS 136.
    Katlama C; Valantin MA; Algarte-Genin M; Duvivier C; Lambert-Niclot S; Girard PM; Molina JM; Hoen B; Pakianather S; Peytavin G; Marcelin AG; Flandre P
    AIDS; 2010 Sep; 24(15):2365-74. PubMed ID: 20802297
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Virologic Effectiveness of Abacavir/Lamivudine with Darunavir/Ritonavir Versus Other Protease Inhibitors in Treatment-Experienced HIV-Infected Patients in Clinical Practice.
    Lackey P; Mills A; Carpio F; Hsu R; DeJesus E; Pierone G; Henegar C; Fusco J; Fusco G; Wohlfeiler M
    Clin Drug Investig; 2017 Jan; 37(1):51-60. PubMed ID: 27587070
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of once-daily ritonavir-boosted atazanavir or darunavir in combination with a dual nucleos(t)ide analogue backbone in HIV-1-infected combined ART (cART)-naive patients with severe immunosuppression: a 48 week, non-comparative, randomized, multicentre trial (IMEA 040 DATA trial).
    Slama L; Landman R; Assoumou L; Benalycherif A; Samri A; Joly V; Pialoux G; Valin N; Cabié A; Duvivier C; Lambert-Niclot S; Marcelin AG; Peytavin G; Costagliola D; Girard PM;
    J Antimicrob Chemother; 2016 Aug; 71(8):2252-61. PubMed ID: 27068399
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Refining criteria for selecting candidates for a safe lopinavir/ritonavir or darunavir/ritonavir monotherapy in HIV-infected virologically suppressed patients.
    Gianotti N; Cozzi-Lepri A; Antinori A; Castagna A; De Luca A; Celesia BM; Galli M; Mussini C; Pinnetti C; Spagnuolo V; d'Arminio Monforte A; Ceccherini-Silberstein F; Andreoni M;
    PLoS One; 2017; 12(2):e0171611. PubMed ID: 28192453
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 96 week results from the MONET trial: a randomized comparison of darunavir/ritonavir with versus without nucleoside analogues, for patients with HIV RNA <50 copies/mL at baseline.
    Clumeck N; Rieger A; Banhegyi D; Schmidt W; Hill A; Van Delft Y; Moecklinghoff C; Arribas J
    J Antimicrob Chemother; 2011 Aug; 66(8):1878-85. PubMed ID: 21652619
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and pharmacodynamics of the nucleoside sparing dual regimen containing rilpivirine plus darunavir/ritonavir in treatment-naïve HIV-1-infected individuals.
    Jackson A; Else L; Higgs C; Karolia Z; Khoo S; Back D; Devitt E; Pozniak A; Boffito M
    HIV Clin Trials; 2018 Feb; 19(1):31-37. PubMed ID: 29189101
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Simplification from twice-daily to once-daily darunavir/ritonavir in a randomized trial among HIV-infected persons with HIV-1 RNA suppression on antiretroviral therapy.
    Huhn GD; Sigman A; Livak B
    Antivir Ther; 2015; 20(8):849-54. PubMed ID: 25881614
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of Once/Day Dolutegravir Plus Boosted Darunavir as a Switch Strategy in Heavily Treated Patients with Human Immunodeficiency Virus.
    Navarro J; Santos JR; Silva A; Burgos J; Falcó V; Ribera E; Imaz A; Curran A
    Pharmacotherapy; 2019 Apr; 39(4):501-507. PubMed ID: 30723941
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.